Table 1. Patients and clinical characteristics.
| Characteristics | Total (n=152) | Chemoradiation (n=94) | Chemoradiation + ICI (n=58) | P value |
|---|---|---|---|---|
| Age (years), median (IQR) | 59.0 (54.0–66.0) | 59 (53.0–66.3) | 62 (54.8–65.0) | 0.590 |
| Gender, n (%) | 0.103 | |||
| Female | 23 (15.1) | 18 (19.1) | 5 (8.6) | |
| Male | 129 (84.9) | 76 (80.9) | 53 (91.4) | |
| Histology, n (%) | 0.478 | |||
| Squamous | 65 (42.8) | 37 (39.4) | 28 (48.3) | |
| Adenocarcinoma | 50 (32.9) | 35 (37.2) | 15 (25.9) | |
| SCLC | 22 (14.5) | 14 (14.9) | 8 (13.8) | |
| Other | 15 (9.9) | 8 (8.5) | 7 (12.1) | |
| Stage, n (%) | <0.001 | |||
| III | 111 (73.0) | 81 (86.2) | 30 (51.7) | |
| IV | 41 (27.0) | 13 (13.8) | 28 (48.3) | |
| Smoking history, n (%) | 0.491 | |||
| Never | 84 (55.3) | 54 (57.4) | 30 (51.7) | |
| Former | 68 (44.7) | 40 (42.6) | 28 (48.3) | |
| ICI type, n (%) | ||||
| PD-1 inhibitor | 48 (82.8) | |||
| PD-L1 inhibitor | 10 (17.2) | |||
| History of chronic lung disease, n (%) | 0.451 | |||
| Yes | 19 (12.5) | 10 (10.6) | 9 (15.5) | |
| No | 133 (87.5) | 84 (89.4) | 49 (84.5) | |
| Irradiation site, n (%) | 0.586 | |||
| Upper lobe | 101 (66.4) | 64 (68.1) | 37 (63.8) | |
| Lower lobe | 51 (33.6) | 30 (31.9) | 21 (36.2) | |
| Dosimetric parameters, median (IQR) | ||||
| Dose (Gy) | 50 (50.0–60.0) | 60 (50.0–60.0) | 0.088 | |
| V5 (%) | 46.0 (40.8–54.0) | 46.0 (35.0–52.0) | 0.325 | |
| V10 (%) | 36.0 (28.0–40.3) | 35.0 (25.0–38.4) | 0.163 | |
| V20 (%) | 26.5 (20.8–30.0) | 25.0 (17.8–28.3) | 0.057 | |
| V30 (%) | 18.0 (14.0–20.0) | 17.0 (10.8–20.0) | 0.277 | |
| MLD (cc) | 1,374.5 (1,109.3–1,480.6) | 1,333.9 (1,049.8–1,476.1) | 0.397 | |
| PTV (cc) | 465.6 (309.8–667.3) | 433.7 (258.0–525.7) | 0.276 | |
| Lung all (cc) | 3,275.5 (2,931.5–3,826.8) | 3,590.0 (2,820.7–4,312.4) | 0.111 | |
ICI, immune checkpoint inhibitor; IQR, interquartile range; SCLC, small cell lung cancer; PD-1, programmed cell death protein-1; PD-L1, programmed death ligand-1; MLD, mean lung dose; PTV, planned target volume.